eyestock logo

eyestock

SY

Spyre Therapeutics IncNASDAQ SYRE

Последний отчетный период 30 июня, 2024

Обновлено 21 нояб., 2024

Последняя цена

Капитализация млрд. $

1.426

Small

Биржа

XNAS - Nasdaq

Анализ акций SYRE

SY

Нет оценки

Количественный анализ Eyestock не покрывает акции Spyre Therapeutics Inc.

Капитализация млрд. $

1.426

Дивидендная доходность

Оборот

50.78 млрд

Сайт компании

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2016-04-07. The firm is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. The company has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Смотреть Секцию: Рейтинг